Theoretical proposal: Allele dosage of MAP2K4/MKK4 could rationalize frequent 17p loss in diverse human cancers

Cell Cycle

Volumn 5, Issue 10, 2006, Pages 1090-1093

  Cunningham, Steven C ^a,c   Gallmeier, Eike ^a   Hucl, Tomas ^a   Dezentje, David A ^a   Abdelmohsen, Kotb ^b   Gorospe, Myriam ^b   Kern, Scott E ^a,d  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b NATIONAL INSTITUTE ON AGING   (United States)

^c UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Gene dosage; Haploinsufficiency; Human; Mkk4; p53; Targeted disruption

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; PROTEIN P53;

ARTICLE; CANCER; CANCER CELL; CHROMOSOME 17P; CHROMOSOME LOSS; ENZYME PHOSPHORYLATION; GENE DOSAGE; GENE INACTIVATION; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; PHENOTYPE; SOMATIC CELL; THEORETICAL STUDY;

EID: 33646816786     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.5.10.2805     Document Type: Article

References (30)

1. Iacobuzio-Donahue CA, van der Heijden MS, Baumgartner MR, Troup WJ, Romm JM, Doheny K, Pugh E, Yeo CJ, Goggins MG, Hruban RH, Kern SE. Large-scale allelotype of pancreaticobiliary carcinoma provides quantitative estimates of genome-wide allelic loss. Cancer Res 2004; 64:871-5.
2. Moore PS, Beghelli S, Zamboni G, Scarpa A. Genetic abnormalities in pancreatic cancer. Mol Cancer 2003; 2:7.
3. Kern SE, Pietenpol JA, Thiagalingam S, Seymour A, Kinzler KW, Vogelstein B. Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 1992; 256:827-30.
4. Redston MS, Caldas C, Seymour AB, Hruban RH, da Costa L, Yeo CJ, Kern SE. p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res 1994; 54:3025-33.
5. 2 arrest after DNA damage. Science 1998; 282:1497-501.
6. Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L, Williams J, Lengauer C, Kinzler KW, Vogelstein B. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 1999; 104:263-9.
7. Piette J, Neel H, Marechal V. Mdm2: Keeping p53 under control. Oncogene 1997; 15:1001-10.
8. Minet E, Michel G, Mottet D, Piret JP, Barbieux A, Raes M, Michiels C. c-JUN gene induction and AP-1 activity is regulated by a JNK-dependent pathway in hypoxic HepG2 cells. Exp Cell Res 2001; 265:114-24.
9. Bagowski CP, Besser J, Frey CR, Ferrell Jr JE. The JNK cascade as a biochemical switch in mammalian cells: Ultrasensitive and all-or-none responses. Curr Biol 2003; 13:315-20.
10. Adler V, Qu Y, Smith SJ, Izotova L, Pestka S, Kung HF, Lin M, Friedman FK, Chie L, Chung D, Boutjdir M, Pincus MR. Functional interactions of Raf and MEK with Jun-N-terminal kinase (JNK) result in a positive feedback loop on the oncogenic Ras signaling pathway. Biochemistry 2005; 44:10784-95.
11. Hruban RH, Goggins M, Parsons J, Kern SE. Progression model for pancreatic cancer. Clin Cancer Res 2000; 6:2969-72.
12. Sanchez I, Hughes RT, Mayer BJ, Yee K, Woodgett JR, Avruch J, Kyriakis JM, Zon LI. Role of SAPK/ERK kinase-1 in the stress-activated pathway regulating transcription factor c-Jun. Nature 1994; 372:794-8.
13. Derijard B, Raingeaud J, Barrett T, Wu IH, Han J, Ulevitch RJ, Davis RJ. Independent human MAP-kinase signal transduction pathways defined by MEK and MKK isoforms. Science 1995; 267:682-5.
14. Cuenda A. Mitogen-activated protein kinase kinase 4 (MKK4). Int J Biochem Cell Biol 2000; 32:581-7.
15. Tournier C, Dong C, Turner TK, Jones SN, Flavell RA, Davis RJ. MKK7 is an essential component of the JNK signal transduction pathway activated by proinflammatory cytokines. Genes Dev 2001; 15:1419-26.
16. Yang D, Tournier C, Wysk M, Lu HT, Xu J, Davis RJ, Flavell RA. Targeted disruption of the MKK4 gene causes embryonic death, inhibition of c-Jun NH2-terminal kinase activation, and defects in AP-1 transcriptional activity. Proc Natl Acad Sci USA 1997; 94:3004-9.
17. Dong C, Yang DD, Tournier C, Whitmarsh AJ, Xu J, Davis RJ, Flavell RA. JNK is required for effector T-cell function but not for T-cell activation. Nature 2000; 405:91-4.
18. Angel P, Karin M. The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochim Biophys Acta 1991; 1072:129-57.
19. Teng DH, Perry IIIrd WL, Hogan JK, Baumgard M, Bell R, Berry S, Davis T, Frank D, Frye C, Hattier T, Hu R, Jammulapati S, Janecki T, Leavitt A, Mitchell JT, Pero R, Sexton D, Schroeder M, Su PH, Swedlund B, Kyriakis JM, Avruch J, Bartel P, Wong AK, Tavtigian SV, et al. Human mitogen-activated protein kinase kinase 4 as a candidate tumor suppressor. Cancer Res 1997; 57:4177-82.
20. Su GH, Hilgers W, Shekher MC, Tang DJ, Yeo CJ, Hruban RH, Kern SE. Alterations in pancreatic, biliary, and breast carcinomas support MKK4 as a genetically targeted tumor suppressor gene. Cancer Res 1998; 58:2339-42.
21. Parsons DW, Wang TL, Samuels Y, Bardelli A, Cummins JM, DeLong L, Silliman N, Ptak J, Szabo S, Willson JK, Markowitz S, Kinzler KW, Vogelstein B, Lengauer C, Velculescu VE. Colorectal cancer: Mutations in a signalling pathway. Nature 2005; 436:792.
22. Winter J. No homozygous deletions in MKK7 in pancreatic cancer. Journal of Negative Observations in Genetic Oncology 2005; 9:1.
23. Kennedy NJ, Davis RJ. Role of JNK in tumor development. Cell Cycle 2003; 2:199-201.
24. Yoshida S, Fukino K, Harada H, Nagai H, Imoto I, Inazawa J, Takahashi H, Teramoto A, Emi M. The c-Jun NH2-terminal kinase3 (JNK3) gene: Genomic structure, chromosomal assignment, and loss of expression in brain tumors. J Hum Genet 2001; 46:182-7.
25. Nowell PC. The clonal evolution of tumor cell populations. Science 1976; 194:23-8.
26. Burch PR. Natural and radiation carcinogenesis in Man. Ii. natural leukaemogenesis: Initiation. Proc R Soc Lond B Biol Sci 1965; 162:240-63.
27. Cunningham SC, Gallmeier E, Hucl T, Dezentje DA, Calhoun ES, Falco G, Abdelmohsen K, Gorospe M, Kern SE. Targeted deletion of MKK4 in cancer cells: A detrimental phenotype manifests as decreased experimental metastasis and suggests a counterweight to the evolution of tumor-suppressor loss. Cancer Res 2006; In press.
28. Payne SR, Kemp CJ. Tumor suppressor genetics. Carcinogenesis 2005; 26:2031-45.
29. Fang Y, Tsao CC, Goodman BK, Furumai R, Tirado CA, Abraham RT, Wang XF. ATR functions as a gene dosage-dependent tumor suppressor on a mismatch repair-deficient background. EMBO J 2004; 23:3164-74.
30. Weinberg RA. Tumor suppressor genes. Science 1991; 254:1138-46.